Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. sinusitis
Show results for
Products
Services
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Sinusitis Articles & Analysis

25 news found

Infrared Coagulation of The Inferior Turbinate: A new treatment for refractory chronic rhinitis

Infrared Coagulation of The Inferior Turbinate: A new treatment for refractory chronic rhinitis

Infective CR is usually caused by sinusitis, whereas 48% of noninfective CR (NICR) is allergic (ACR), 15% nonallergic eosinophilic (NAECR), and 37% vasomotor (VMCR) in origin.2 The estimated incidence of allergic rhinitis in the United States is 24 million.3 One quarter of these cases are chronic,4 which implies that approximately one person in every four households has NICR. ...

ByRedfield Corporation


Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection

Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection

Ondine’s photodisinfection is a platform technology under development for a wide variety of conditions including presurgical decolonisation, and treatment of burns, wounds, ventilator-associated pneumonia, and chronic sinusitis. “The rising rates of COVID-19 due to rapidly evolving SARS-CoV-2 variants underline the importance of our broad-spectrum nasal ...

ByOndine Biomedical Inc


WHO calls for new innovations to tackle antimicrobial resistance crisis

WHO calls for new innovations to tackle antimicrobial resistance crisis

While photodisinfection is initially focussed on preventing HAIs, the technology can be used widely to kill pathogens in many applications such as burns, ulcers, sinusitis, skin infections — anywhere the photosensitizer liquid can be activated by a specific wavelength of light. ...

ByOndine Biomedical Inc


Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. ...

ByVertex Pharmaceuticals


Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. Despite universal vaccination for PD in infants and in many adults in the United States, the overall incidence of PD is substantial and is driven by emerging serotypes not covered by currently available vaccines. ...

ByVaxcyte, Inc.


Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. The global incidence of PD is driven by emerging serotypes not covered by currently available vaccines. ...

ByVaxcyte, Inc.


Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL Sinus Implant Reduces Healthcare Resource Utilization

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL Sinus Implant Reduces Healthcare Resource Utilization

Intersect ENT’s PROPEL sinus implants uniquely provide mechanical stenting of a patient’s sinuses while providing localized delivery of the corticosteroid mometasone furoate directly to healing sinus tissue, features that have been shown previously to improve outcomes after sinus surgery.1-3 “As one of the first observational studies to use real-world evidence ...

ByIntersect ENT, Inc.


Lyra Therapeutics Announces Initiation Of Lyr-210 Pivotal Phase 3 Enlighten Program In Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics Announces Initiation Of Lyr-210 Pivotal Phase 3 Enlighten Program In Surgically Naïve Chronic Rhinosinusitis Patients

Lyra has two product candidates in development for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities: LYR-210, for surgically naïve patients, and LYR-220, for patients who have recurrent symptoms despite surgery. ...

ByLyra Therapeutics, Inc.


Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

It can result in invasive PD (IPD), including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. The global incidence of PD is driven by emerging serotypes not covered by currently available vaccines. ...

ByVaxcyte, Inc.


First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

FESS is used to treat chronic rhinosinusitis, a persistent inflammation of the sinuses that can be debilitating to patients. Intersect ENT’s PROPEL Contour is a drug-eluting, bioabsorbable sinus implant that is placed in the frontal sinus (between the eyebrows) following sinus surgery. ...

ByIntersect ENT, Inc.


Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

The manuscript titled, “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses,” can be accessed online here. The pharmacokinetics and drug release study evaluated the release of mometasone furoate (MF), a potent anti-inflammatory corticosteroid formulated into Lyra’s proprietary XTreo™ ...

ByLyra Therapeutics, Inc.


Medtronic to Acquire Intersect ENT

Medtronic to Acquire Intersect ENT

It is one of the top 10 most costly medical conditions for employers, with most patients reporting 5-15+ years of suffering and medical treatment.1-3 Intersect ENT's PROPEL implant – used primarily in hospitals and ambulatory surgery centers – is a bioabsorbable, drug-eluting implant inserted after sinus surgery to keep passageways open and deliver an anti-inflammatory steroid to the ...

ByIntersect ENT, Inc.


U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

As many as 1 in 8 adults in the United States suffer from CRS, a condition in which the sinuses within the nose and head become swollen and inflamed for three months or longer, causing blockage of airflow and drainage. Over time, the sinuses can become infected leading to inflammation and pain. Up to 60% of CRS patients may not experience significant improvements ...

ByIntersect ENT, Inc.


Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

PROPEL Contour features an innovative hourglass shape, specifically designed for placement in the frontal sinuses (between the eyebrows) following sinus surgery for chronic rhinosinusitis patients. ...

ByIntersect ENT, Inc.


Expand Post-Market Study Evaluating Longer-Term Outcomes of PROPEL Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation

Expand Post-Market Study Evaluating Longer-Term Outcomes of PROPEL Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation

Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. ...

ByIntersect ENT, Inc.


Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL Mini Sinus Implant

Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL Mini Sinus Implant

“We are dedicated to responding to our customers’ feedback and providing them with the best combination of products to advance care for chronic sinusitis patients in various centers of care.” “The combination of the PROPEL Mini and the Straight Delivery System in one package is reflective of Intersect ENT’s ongoing commitment to supporting the ENT ...

ByIntersect ENT, Inc.


Miamitech Startup Spotlight: Dalent Aims to Improve Sinus Surgery Experience, Outcome and Cost

Miamitech Startup Spotlight: Dalent Aims to Improve Sinus Surgery Experience, Outcome and Cost

But most of us don’t have Chronic Sinusitis, which consists of a sinus infection lasting longer than 3 months (despite treatment), according to the Mayo Clinic. ...

ByDalent Medical


SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy

SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy

” Repeated application of NORSTM has been demonstrated to be safe and potentially effective in patients with chronic sinusitis. Further trials have demonstrated its effectiveness in-vitro against viruses, including influenza A, hCoV-OC43 and H1N1. ...

BysaNOtize Research and Development Corp.


Sinusleeve™ Balloon Device Completes FDA Listing, Dalent Medical Begins Sales in South Florida

Sinusleeve™ Balloon Device Completes FDA Listing, Dalent Medical Begins Sales in South Florida

The Sinusleeve™ Balloon is a single-use, disposable, balloon sinus dilation device (BSD) used for treating chronic sinusitis. Developed and manufactured in the United States, this patented device fits over rigid, flexible and reusable positioning and suction devices by way of a conforming sleeve. ...

ByDalent Medical


Dalent Medical Secures $1.5 Million Round, Granted Patent Protecting New Medical Device for ENT Physicians

Dalent Medical Secures $1.5 Million Round, Granted Patent Protecting New Medical Device for ENT Physicians

The balloon sinus dilation sleeve will be used by ENT’s in procedures that treat Chronic Sinusitis, a condition which affects up to 30 million people in the United States. ...

ByDalent Medical

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT